Categories
We’ve answered many different kinds of questions for many different organisations in over 70 countries. They include:
How will the types of jobs UK adults do affect whether or not they’re obese?
We looked forward to 2035 to see what kind of impact social inequality will have on obesity. We found that by then, UK people aged 16 and older working in routine or manual jobs will have the highest levels of, and greatest increases in, obesity.
How many lives could a tobacco tax save in the Ukraine?
The World Bank asked us to look at a specific tobacco tax increase in the Ukraine, modelling its impact between now and 2035. We showed that it would prevent 29,172 premature deaths and 126,730 new cases of smoking-related disease. These findings, supported by evidence from the WHO Taxsim model, helped the Ukrainian government decide to enact the tax increase.
How can the NHS best help severely obese adults manage their weight?
Our REBALANCE project, a collaboration with the University of Oxford, analysed the impact of different weight management programmes on severely obese over-18 year olds. That helped the NHS assess and understand the long-term cost-effectiveness of these programs, then choose which one to go ahead with.
How can changing the prices of goods and services affect people’s health?
Public Health England asked us to help policy and decision makers understand how tax and pricing changes can change consumer choices, and through that improve their health. We looked at a range of different existing policies, then created a reference database of the ones that had definitely worked. It shows people where the evidence for the success of those policies is strongest and where there are gaps in the literature.
What’s the best way of reducing liver disease across Europe?
The European Association for the Study of the Liver came to us with some very specific questions about liver disease. We created the HEPAHEALTH database, which synthesised epidemiological, risk factor and intervention data about it. The database helped its users reduce liver disease levels across 35 European countries.